Viracta Therapeutics (VIRX)

Viracta Therapeutics (VIRX) Stock Price & Analysis


VIRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.21 - $5.75
Previous Close$1.4
Average Volume (3M)87.73K
Market Cap
Enterprise Value-$6.66M
Total Cash (Recent Filing)$91.04M
Total Debt (Recent Filing)$25.16M
Price to Earnings (P/E)-1.1
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding38,410,935
10 Day Avg. Volume54,350
30 Day Avg. Volume87,730
Standard Deviation0.33
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.14
Price Target Upside1185.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Viracta Therapeutics’s price range in the past 12 months?
Viracta Therapeutics lowest stock price was $1.21 and its highest was $5.75 in the past 12 months.
    What is Viracta Therapeutics’s market cap?
    Currently, no data Available
    When is Viracta Therapeutics’s upcoming earnings report date?
    Viracta Therapeutics’s upcoming earnings report date is May 10, 2023 which is in 44 days.
      How were Viracta Therapeutics’s earnings last quarter?
      Viracta Therapeutics released its earnings results on Mar 13, 2023. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.364 by $0.094.
        Is Viracta Therapeutics overvalued?
        According to Wall Street analysts Viracta Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Viracta Therapeutics pay dividends?
          Viracta Therapeutics does not currently pay dividends.
          What is Viracta Therapeutics’s EPS estimate?
          Viracta Therapeutics’s EPS estimate is -$0.32.
            How many shares outstanding does Viracta Therapeutics have?
            Viracta Therapeutics has 38,410,934 shares outstanding.
              What happened to Viracta Therapeutics’s price movement after its last earnings report?
              Viracta Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.364. Following the earnings report the stock price went up 2.941%.
                Which hedge fund is a major shareholder of Viracta Therapeutics?
                Among the largest hedge funds holding Viracta Therapeutics’s share is Aisling Capital Management LP. It holds Viracta Therapeutics’s shares valued at 421K.


                  Viracta Therapeutics Stock Smart Score

                  The Viracta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Viracta Therapeutics

                  Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.


                  Top 5 ETFs holding VIRX

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold VIRX. The ETFs are listed according to market value of VIRX within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Aziyo Biologics
                  Shattuck Labs
                  Spectrum Pharmaceuticals
                  vTv Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis